Candel Therapeutics, Inc. (CADL) Appoints Maria Ostrovsky as General Counsel

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

Candel Therapeutics (CADL) reported Phase 2a trial results for aglatimagene in NSCLC patients. Median overall survival was 24.5 months in the evaluable population. The treatment showed systemic immune responses and was generally well tolerated. Candel is advancing to a Phase 3 trial. CADL stock is currently at $10.39, down 0.67%.

Candel Therapeutics reported Phase 2a results showing 24.5-month median overall survival for aglatimagene plus valacyclovir in unresectable stage III/IV NSCLC with inadequate ICI response, compared to 9.8–11.8 months in docetaxel benchmarks. The company aims for a pivotal Phase 3 trial to confirm these findings.

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.